2013•Annals of the New York Academy of SciencesOpen access

Achieving cancer cell death with PI3K/mTOR‐targeted therapies

Sung Su Yea, David A. Fruman

Abstract

Inhibitors of the PI3K/mTOR signaling network are under development as novel cancer therapies. However, these compounds do not cause robust cytotoxic responses in tumor cells unless combined with other agents. Rational combinations with other targeted therapies will likely be necessary to achieve the potential of PI3K/mTOR inhibitors in oncology.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 28 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: PI3K/AKT/mTOR pathway, Discovery and development of mTOR inhibitors, Cancer, Medicine, Cancer research, RPTOR, Signal transduction, Biology